52-biomx PSC

BiomX just presented preclinical data on its development of a phage cocktail active against Klebsiella pneumoniae strains correlated with primary sclerosing cholangitis (PSC) severity. PSC is a liver disease with no FDA-approved treatment that affects 30,000 US patients.